The company also offers Rybelsus ... shortages limited to the lowest dose for Wegovy. Resolving these supply issues will be crucial for Novo Nordisk to capitalize on the growing demand for ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide ... two other semaglutide products – Ozempic and Rybelsus for type 2 diabetes – have been included ...

The EMA's main advisory committee has backed approval of Novo Nordisk's oral GLP-1 agonist Rybelsus ... Vaxchora will be the only single-dose oral vaccine indicated for active immunisation ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Novo Nordisk shares declined on Monday after the company reported that its next-generation weight-loss drug, CagriSema, ...

Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street ...

Danish pharmaceutical giant Novo Nordisk says about 13 million Australians ... in Australia is $460 per month for a 2.4-milligram dose. Doctors say that although the drugs are proven to help ...

Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...